drugset / Trial / NCT00126230
Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | samarium | Unknown | — | — |